Baili Pharmaceutical

Executive Summary

Baili Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing novel small molecule therapies for oncology and metabolic diseases. Founded in 2010, the company leverages structure-based drug design to create targeted therapies with improved efficacy and safety profiles. Its pipeline includes multiple candidates in various stages of development, with a primary emphasis on oncology indications that address significant unmet medical needs. The company's approach combines deep expertise in medicinal chemistry with a robust understanding of disease biology, positioning it to deliver innovative treatments in the rapidly evolving Chinese pharmaceutical market. The company has advanced its lead oncology candidate into Phase 2 clinical trials, with initial data expected to demonstrate proof-of-concept and support further development. Additionally, Baili is progressing preclinical programs in metabolic diseases, targeting indications such as diabetes and obesity. The company's strategy includes potential partnerships with larger pharmaceutical companies to accelerate development and commercialization. With a strong intellectual property portfolio and a focus on high-value targets, Baili Pharmaceutical is well-positioned to capture value in the growing Chinese biotech sector. Key upcoming milestones include Phase 2 data readouts and regulatory interactions that will shape the company's trajectory.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead oncology candidate60% success
• Q4 2026IND filing for first metabolic disease candidate70% success
• Q2 2026Potential strategic partnership for China co-development rights50% success